Benefits
Caffeine-free alertness and mental focus
Five human RCTs demonstrate enXtra® significantly improves alertness, attention, and cognitive performance for up to 5 hours post-dose without caffeine or stimulant mechanisms. This makes it uniquely valuable for caffeine-sensitive populations, evening use, or as a non-stimulant nootropic foundation.
Caffeine duration extension and synergy
A landmark double-blind crossover RCT found enXtra® combined with 40 mg caffeine sustained cognitive benefits for the full 5-hour study period — while caffeine alone showed declining effects after 1–2 hours. enXtra® appears to extend caffeine's window of cognitive efficacy, enabling lower caffeine doses to provide longer-lasting focus.
Sustained attention and processing speed
enXtra® improves performance on sustained attention tasks, reaction time, and information processing speed — cognitive domains critical for productivity, sport performance, and academic performance. Effects are maintained throughout the day without the afternoon crash associated with caffeine or stimulants.
Mood and wellbeing support
Clinical studies report improved subjective mood, reduced mental fatigue, and enhanced overall wellbeing with enXtra® supplementation. These effects occur through non-adrenergic mechanisms, distinguishing enXtra® from stimulant-based energy products.
Mechanism of action
Dopamine and acetylcholine pathway modulation
Acetoxy chavicol acetate (ACA) and related phenylpropanoids from A. galanga modulate dopaminergic and cholinergic neurotransmitter pathways — increasing dopamine availability in prefrontal cortex circuits governing attention and motivation, and enhancing acetylcholine signaling for working memory and learning.
PDE inhibition and cyclic AMP elevation
Galangal constituents inhibit phosphodiesterase (PDE) enzymes, raising intracellular cyclic AMP levels in neurons. Elevated cAMP activates PKA signaling cascades that enhance synaptic plasticity, working memory, and the cellular mechanisms of attention — a fundamentally different mechanism from caffeine's adenosine antagonism.
Non-adrenergic alertness mechanism
Unlike stimulants that trigger norepinephrine and epinephrine release via adrenergic pathways, enXtra® produces alertness through CNS-specific mechanisms without peripheral cardiovascular activation. This explains why enXtra® does not increase heart rate or blood pressure at clinical doses.
Clinical trials
Randomized, double-blind, double-dummy, placebo-controlled crossover study evaluating Alpinia galanga (E-AG-01 / enXtra® 300 mg), caffeine (40 mg), placebo, and combination on mental alertness and sustained attention in 89 healthy adults. Cognitive testing performed at baseline, 1, 3, and 5 hours post-dose. (Srivastava, Mennemeier, Pimple 2017, J Am Coll Nutr)
89 healthy adults. Acute crossover design.
enXtra® alone significantly increased alertness scores at 1, 3, and 5 hours vs placebo. Caffeine alone produced an early peak (1 hour) followed by decline. The combination (enXtra® + caffeine) produced sustained alertness benefits across the entire 5-hour window. Authors propose enXtra® as a non-stimulant alertness enhancer with caffeine-extending properties.
Randomized, double-blind, placebo-controlled trial in healthy adults receiving enXtra® alone, enXtra® + caffeine, or placebo for 12 weeks. Cardiovascular safety assessed via QT interval, blood pressure, heart rate. Efficacy outcomes: Bond and Lader mood scales (alertness, calmness), Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale. (Srivastava, Mennemeier, Chaudhary 2021, J Am Coll Nutr)
Healthy adults. 12-week intervention.
No significant changes in ECG or hemodynamic parameters (no cardiovascular risk). Alertness and calmness scores significantly increased in enXtra® and enXtra® + caffeine groups (p<0.001). Sleep quality (PSQI) remained undisturbed across all arms — confirming non-stimulant mechanism. Daytime sleepiness scores decreased in enXtra® group (non-significant trend). Confirmed long-term safety profile.
Randomized, double-blind, placebo-controlled, cross-over clinical interventional study in 62 subjects randomized to enXtra® (300 mg) or placebo daily for 28 days, then crossover. Primary endpoint: mental alertness assessed by Symbol Digit Coding test, Shifting Attention test, Stroop Test, and Alertness Rating Scale (CNS Vital Signs). Secondary: daytime sleepiness, fatigue, energy, vigilance. (Eraiah et al. 2023)
62 healthy adults. 4-week supplementation with cross-over.
enXtra® significantly improved alertness, focus, and energy scores vs placebo across the 28-day period. Daytime sleepiness and fatigue were reduced. No safety concerns. Sustained effects with chronic use, complementing acute-effect data from prior trials.